ReviewJapanese journal of radiology2026
Malignant potential of intraductal papillary mucinous neoplasm (IPMN) of the pancreas: imaging assessment of IPMN-derived cancer and concomitant pancreatic ductal adenocarcinoma.
Review in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The detection of pancreatic cystic lesions (PCLs) has increased markedly with the widespread use of cross-sectional imaging. Although the true proportion of intraductal papillary mucinous neoplasms (IPMNs) among PCLs remains uncertain, IPMN is considered to account for most PCLs and is a representative precursor lesion of pancreatic ductal adenocarcinoma (PDAC). However, not all PCLs should be assumed to represent IPMN, because this assumption may lead to unnecessary surveillance or overtreatment. Therefore, radiologists should first determine whether a PCL truly represents IPMN, particularly by differentiating it from lesions without malignant potential, such as serous cystic neoplasm. Once IPMN is diagnosed, appropriate risk stratification is required to identify IPMN-derived cancer, defined in this review as IPMN with high-grade dysplasia or associated invasive carcinoma. High-risk stigmata and worrisome features proposed in current guidelines are central to this assessment. However, the risk associated with each factor is not uniform; therefore, risk assessment and management decisions should consider both the number of risk factors present and the relative weight of each factor. Concomitant PDAC may also arise separately from the PCL, possibly reflecting a field defect of the entire pancreas. Unlike IPMN-derived cancer, concomitant PDAC may develop independently of cyst size or growth and is often detected at an advanced stage. Therefore, surveillance of patients with IPMN should include not only evaluation of the PCL itself and assessment for IPMN-derived cancer, but also systematic assessment of the entire pancreas for concomitant PDAC. This review discusses the differential diagnosis of PCLs, imaging assessment of IPMN-derived cancer, the concept and imaging clues of concomitant PDAC, and practical considerations for surveillance strategies.
Indexed as
Identifiers
42669110What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.